Loading…
Uses AI and synthetic biology to design novel antibody drug candidates for pharma partners and its own pipeline.
Uses AI and synthetic biology to design novel antibody drug candidates for pharma partners and its own pipeline.
Pharma partners pay research fees and milestone payments for antibodies the platform designs, with royalties only if those drugs are sold, so revenue is small and irregular. It pays for its own programmes by raising capital from investors.
Moat: narrow (data, IP / patents, process know-how). Combines generative AI with wet-lab synthetic biology to design antibodies faster than traditional discovery.
Headquarters: Vancouver, Washington, US · Founded: 2011 · Employees: 140
Size Absci (ABSI) is a United States Health Care company (Biotechnology) with a market value of $1.75B, the 1888th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.17 on 6 Nov 2026.
Performance Over six months the shares gained 72.4%, against -2.2% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue fell 62.3% over the last twelve months (peer median +20.2%); the operating margin is -8,411.3% (peer median -43.2%).
Valuation It trades at 991.7× enterprise value to sales against a peer median of 15.0× (2nd most expensive of 19).
Short interest Short interest is 21.6% of the free float (15 Oct 2026).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.56M | $2.80M | $4.53M | $5.72M | $5.75M |
| Revenue growth | — | -38% | -21% | -1% | — |
| Gross profit | -$9.53M | -$8.94M | -$8.86M | -$8.28M | -$7.29M |
| EBITDA | -$120M | -$113M | -$95.5M | -$79.7M | -$93.7M |
| Net income | -$121M | -$115M | -$103M | -$111M | -$105M |
| Free cash flow | -$109M | -$94.0M | -$72.8M | -$65.5M | -$97.5M |
| Capital expenditure | $890,000 | $1.11M | $404,000 | $860,000 | $16.2M |
| Total debt | $3.83M | $5.30M | $10.1M | $16.0M | $23.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Absci ABSI | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a |
| AbCellera Biologics ABCL | $3.85B | +149% | +101% | -340% | 51.7× | n/a |
| Recursion Pharmaceuticals RXRX | $2.19B | +6% | +56% | -725% | 25.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABSI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.8% | -9.9% | 2nd highest of 20 |
| 6-month return | +72.4% | -2.2% | highest of 19 |
| Distance from 52-week high | -18.9% | -38.6% | highest of 20 |
| Revenue growth (TTM) | -62.3% | +20.2% | 3rd lowest of 20 |
| Operating margin | -8,411.3% | -43.2% | 2nd lowest of 20 |
| EV / Sales | 991.7× | 15.0× | 2nd most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.73B | +21% | +30% | -4% | 8.5× | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | 15.2× | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | 1,588.4× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 6.5× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |